Trial Profile

A trial of pharmacokinetics and safety of OXL001 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OXL 001 (Primary)
Indications Cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Oxilio

Most Recent Events

06 Nov 2022 According to an Oxilio media release, first subject had been dosed in this study
06 Nov 2022 Status changed from planning to recruiting as per Oxilio media release
04 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com